MYOKARDIA,INC. (NASDAQ:MYOK) Files An 8-K Financial Statements and ExhibitsItem 9.01
(d)Exhibits.
|
ExhibitNo. |
Description |
| 1.1 | Underwriting Agreement, dated August 8, 2017, by and among MyoKardia, Inc. and J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters named therein |
| 5.1 | Opinion of Goodwin Procter LLP |
| 23.1 | Consent of Goodwin Procter LLP (included in Exhibit 5.1) |
| 99.1 | Press Release, dated August 7, 2017 |
| 99.2 | Press Release, dated August 8, 2017 |
MyoKardia Inc ExhibitEX-1.1 2 d398766dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Execution Version MYOKARDIA,…To view the full exhibit click here
About MYOKARDIA,INC. (NASDAQ:MYOK)
MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that results from biomechanical defects in cardiac muscle contraction. It is engaged in the business of developing and commercializing therapeutics. Its pipeline includes over four therapeutic programs for the chronic treatment of over two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Its lead product candidate, MYK-461, is an orally-administered small molecule that reduces cardiac muscle contractility leading to HCM. In preclinical models of HCM, MYK-461 has been shown to prevent and reverse disease progression and to reduce left ventricular outflow tract obstruction. It is evaluating MYK-461 in over three Phase I clinical trials, including approximately two single ascending dose (SAD) trials and over one multiple ascending dose (MAD) trial.
